Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Beyond Air Inc

XAIR
Current price
0.51 USD +0.029 USD (+6.00%)
Last closed 0.48 USD
ISIN US08862L1035
Sector Healthcare
Industry Medical Devices
Exchange NASDAQ
Capitalization 35 379 144 USD
Yield for 12 month -74.56 %
1Y
3Y
5Y
10Y
15Y
XAIR
21.11.2021 - 28.11.2021

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. Address: 900 Stewart Avenue, Garden City, NY, United States, 11530

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.75 USD

P/E ratio

Dividend Yield

Current Year

+1 159 000 USD

Last Year

+59 000 USD

Current Quarter

+683 000 USD

Last Quarter

+470 000 USD

Current Year

-1 307 000 USD

Last Year

-555 000 USD

Current Quarter

-333 000 USD

Last Quarter

-513 000 USD

Key Figures XAIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -58 358 000 USD
Operating Margin TTM -1988.43 %
PE Ratio
Return On Assets TTM -63.48 %
PEG Ratio
Return On Equity TTM -219.18 %
Wall Street Target Price 3.75 USD
Revenue TTM 1 783 000 USD
Book Value 0.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1057.6 %
Dividend Yield
Gross Profit TTM 873 190 USD
Earnings per share -1.64 USD
Diluted Eps TTM -1.64 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics XAIR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History XAIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:100
Payout Ratio
Last Split Date 10.01.2017
Dividend Date 10.01.2017

Stock Valuation XAIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 17.7825
Price Sales TTM 19.8425
Enterprise Value EBITDA -4.2332
Price Book MRQ 2.1934

Financials XAIR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators XAIR

For 52 weeks

0.3 USD 2.36 USD
50 Day MA 0.4 USD
Shares Short Prior Month 1 079 431
200 Day MA 1.02 USD
Short Ratio 1.63
Shares Short 1 350 599
Short Percent 2.04 %